Alnylam to Host Additional Events in “RNAi Roundtable” Webcast Series

  Alnylam to Host Additional Events in “RNAi Roundtable” Webcast Series

Business Wire

CAMBRIDGE, Mass. -- July 29, 2014

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, today announced that it has added three new events to its series of
online “RNAi Roundtables” that it is hosting during July and August. Each
event will be webcast live on the Investors section of the company’s website,
www.alnylam.com. An audio replay of the roundtables will be posted on the
Alnylam website approximately three hours after each event.

The newly added RNAi Roundtable topics include:

ALN-PCSsc for the treatment of Hypercholesterolemia
Thursday, August 14 @ 4:00 p.m. – 5:00 p.m. ET

  *Kevin Fitzgerald, Ph.D., Senior Director, Research
  *Moderator: Akshay Vaishnaw, M.D., Ph.D., Executive Vice President and
    Chief Medical Officer
  *Guest Speaker: Christie Ballantyne, M.D., Professor of Medicine,
    Physiology, and Molecular and Human Genetics, and Chief, Department of
    Medicine, Sections of Cardiology and Cardiovascular Research at Baylor
    College of Medicine

ALN-AAT for the treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver
Disease
Wednesday, August 20 @ 12:30 p.m. – 1:30 p.m. ET

  *Rachel Meyers, Ph.D., Vice President, Research and RNAi Lead Development
  *Moderator: Akshay Vaishnaw, M.D., Ph.D., Executive Vice President and
    Chief Medical Officer
  *Guest Speaker: David Brenner, M.D., Vice Chancellor for Health Sciences
    and Dean of the School of Medicine at the University of California, San
    Diego

ALN-AS1 for the treatment of Hepatic Porphyrias
Thursday, August 21 @ 4:00 p.m. – 5:00 p.m. ET

  *Rachel Meyers, Ph.D., Vice President, Research and RNAi Lead Development
  *Moderator: Barry Greene, President and Chief Operating Officer
  *Guest Speaker: Karl Anderson, M.D., FACP, Professor, Departments of
    Preventive Medicine and Community Health (Division of Human Nutrition) and
    Internal Medicine (Division of Gastroenterology), and Director, Porphyria
    Laboratory & Center

These new events complement the series of already scheduled RNAi Roundtables
that the company plans to host. The complete list of RNAi Roundtables,
including links to the replays of the previously held events, can be found at
www.alnylam.com/capella.

Alnylam will be reviewing its progress with ALN-HBV in development for
Hepatitis B Virus (HBV) Infection in an RNAi Roundtable webinar to be held at
9:30 a.m. ET today, and can be accessed by clicking here.

About Alnylam Pharmaceuticals

Alnylam is a biopharmaceutical company developing novel therapeutics based on
RNA interference, or RNAi. The company is leading the translation of RNAi as a
new class of innovative medicines with a core focus on RNAi therapeutics as
genetic medicines, including programs as part of the company’s “Alnylam
5x15^TM” product strategy. Alnylam’s genetic medicine programs are RNAi
therapeutics directed toward genetically defined targets for the treatment of
serious, life-threatening diseases with limited treatment options for patients
and their caregivers. These include: patisiran (ALN-TTR02), an intravenously
delivered RNAi therapeutic targeting transthyretin (TTR) for the treatment of
TTR-mediated amyloidosis (ATTR) in patients with familial amyloidotic
polyneuropathy (FAP); ALN-TTRsc, a subcutaneously delivered RNAi therapeutic
targeting TTR for the treatment of ATTR in patients with TTR cardiac
amyloidosis, including familial amyloidotic cardiomyopathy (FAC) and senile
systemic amyloidosis (SSA); ALN-AT3, an RNAi therapeutic targeting
antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders
(RBD); ALN-CC5, an RNAi therapeutic targeting complement component C5 for the
treatment of complement-mediated diseases; ALN-AS1, an RNAi therapeutic
targeting aminolevulinic acid synthase-1 (ALAS-1) for the treatment of hepatic
porphyrias including acute intermittent porphyria (AIP); ALN-PCS, an RNAi
therapeutic targeting PCSK9 for the treatment of hypercholesterolemia;
ALN-AAT, an RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the
treatment of AAT deficiency-associated liver disease; ALN-TMP, an RNAi
therapeutic targeting TMPRSS6 for the treatment of beta-thalassemia and
iron-overload disorders; ALN-ANG, an RNAi therapeutic targeting
angiopoietin-like 3 (ANGPTL3) for the treatment of genetic forms of mixed
hyperlipidemia and severe hypertriglyceridemia; ALN-AC3, an RNAi therapeutic
targeting apolipoprotein C-III (apoCIII) for the treatment of
hypertriglyceridemia; and other programs yet to be disclosed. As part of its
“Alnylam 5x15” strategy, as updated in early 2014, the company expects to have
six to seven genetic medicine product candidates in clinical development -
including at least two programs in Phase 3 and five to six programs with human
proof of concept - by the end of 2015. Alnylam is also developing ALN-HBV, an
RNAi therapeutic targeting the hepatitis B virus (HBV) genome for the
treatment of HBV infection. The company’s demonstrated commitment to RNAi
therapeutics has enabled it to form major alliances with leading companies
including Merck, Medtronic, Novartis, Biogen Idec, Roche, Takeda, Kyowa Hakko
Kirin, Cubist, GlaxoSmithKline, Ascletis, Monsanto, The Medicines Company, and
Genzyme, a Sanofi company. In March 2014, Alnylam acquired Sirna Therapeutics,
a wholly owned subsidiary of Merck. In addition, Alnylam holds an equity
position in Regulus Therapeutics Inc., a company focused on discovery,
development, and commercialization of microRNA therapeutics. Alnylam
scientists and collaborators have published their research on RNAi
therapeutics in over 200 peer-reviewed papers, including many in the world’s
top scientific journals such as Nature, Nature Medicine, Nature Biotechnology,
Cell, the New England Journal of Medicine, and The Lancet. Founded in 2002,
Alnylam maintains headquarters in Cambridge, Massachusetts. For more
information, please visit www.alnylam.com.

Contact:

Alnylam Pharmaceuticals, Inc.
Cynthia Clayton, 617-551-8207
Vice President, Investor Relations and
Corporate Communications
or
Spectrum
Liz Bryan (Media), 202-955-6222 x2526
 
Press spacebar to pause and continue. Press esc to stop.